OCN-GLP3R-20
GLP3-R
Retatrutide (LY3437943)
Triple-receptor agonist · GLP-1 + GIP + glucagon
Labeled quantity · 20 mg
For laboratory research only. Not for human or veterinary use. This page is educational and does not provide medical advice, dosing, preparation or administration guidance.
Overview
What it is
Retatrutide is an investigational single molecule designed to activate the GLP-1, GIP and glucagon receptors. It is being studied for obesity, type 2 diabetes and related metabolic complications.
The three pathways have complementary roles in appetite, glucose regulation and energy metabolism. Retatrutide remains investigational and has not been approved for consumer use.
Evidence
Research snapshot
In Lilly's Phase 3 TRIUMPH-1 study, the highest-dose efficacy estimand reported an average 28.3% body-weight reduction at 80 weeks in adults with obesity.
Earlier peer-reviewed Phase 2 research established proof of concept for this triple-receptor approach. Full Phase 3 publication and regulatory review remain important.
Reference
Product specifications
Primary sources
Read the research
Research summaries are informational and may not apply to this catalog material. Product identity, purity and suitability require independent verification.